1. Home
  2. CHRS vs APYX Comparison

CHRS vs APYX Comparison

Compare CHRS & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • APYX
  • Stock Information
  • Founded
  • CHRS 2010
  • APYX 1982
  • Country
  • CHRS United States
  • APYX United States
  • Employees
  • CHRS N/A
  • APYX N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • APYX Medical/Dental Instruments
  • Sector
  • CHRS Health Care
  • APYX Health Care
  • Exchange
  • CHRS Nasdaq
  • APYX Nasdaq
  • Market Cap
  • CHRS 102.0M
  • APYX 85.0M
  • IPO Year
  • CHRS 2014
  • APYX 1987
  • Fundamental
  • Price
  • CHRS $1.04
  • APYX $2.54
  • Analyst Decision
  • CHRS Buy
  • APYX Hold
  • Analyst Count
  • CHRS 3
  • APYX 2
  • Target Price
  • CHRS $4.68
  • APYX N/A
  • AVG Volume (30 Days)
  • CHRS 1.3M
  • APYX 103.5K
  • Earning Date
  • CHRS 08-07-2025
  • APYX 08-07-2025
  • Dividend Yield
  • CHRS N/A
  • APYX N/A
  • EPS Growth
  • CHRS N/A
  • APYX N/A
  • EPS
  • CHRS N/A
  • APYX N/A
  • Revenue
  • CHRS $272,251,000.00
  • APYX $47,288,000.00
  • Revenue This Year
  • CHRS N/A
  • APYX $2.25
  • Revenue Next Year
  • CHRS $99.43
  • APYX $6.76
  • P/E Ratio
  • CHRS $2.44
  • APYX N/A
  • Revenue Growth
  • CHRS 19.87
  • APYX N/A
  • 52 Week Low
  • CHRS $0.66
  • APYX $0.76
  • 52 Week High
  • CHRS $2.43
  • APYX $2.73
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 68.96
  • APYX 65.15
  • Support Level
  • CHRS $0.88
  • APYX $2.20
  • Resistance Level
  • CHRS $1.06
  • APYX $2.41
  • Average True Range (ATR)
  • CHRS 0.07
  • APYX 0.24
  • MACD
  • CHRS 0.02
  • APYX 0.01
  • Stochastic Oscillator
  • CHRS 93.38
  • APYX 82.35

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About APYX Apyx Medical Corporation

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Share on Social Networks: